Home page A B C D E F G H I K L M N O P Q R S T U V W X Y Z

Drug Interactions AIDS Education and Training Centers National

Udocheals.orgDrug interactions
5.18.2017 | Jennifer Bargeman
Drug interactions
Drug Interactions AIDS Education and Training Centers National

August 1, 2014. This effect is lessened by coadministration of ritonavir-boosted PIs: the combination of ETR + DTG + darunavir/. New data show that etravirine (ETR) substantially lowers plasma concentrations of dolutegravir (DTG) (DTG Cmin decreased 88%, AUC decreased 71%).

Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. The U.S. October 17, 2014. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy.

Coauthor: Susa Coffey, MD; Medical Editor, AETC National Resource Center.

Antacids, laxatives, mineral supplements, and other compounds that contain metal cations (eg, calcium, magnesium, aluminum, and iron) may decrease levels of integrase inhibitors if taken close in time to each other. November 12, 2013. Results of two studies help to assess the magnitude of this effect and assist in.

April 12, 2016.

May 18, 2012. Pitavastatin is one of the newer statins approved and is one of the few that is not. Treatment of dyslipidemia is often complicated by drug interactions between statins and antiretrovirals.

The following table summarizes recent additions to the HIV InSite Database of Antiretroviral Drug Interactions. May 1, 2013. For a full description of the updates, including references to the studies from which the data were derived, go to the database, click on a specific drug name, and search for the.

Listed below are highlights of some of the. Dolutegravir, the newly approved integrase inhibitor, has a number of important drug interactions with other medications and nutritional products. October 7, 2013.

October 5, 2012. As BOC is an inhibitor of hepatic cytochrome (CYP) 3A4, and many protease inhibitors and NNRTIs affect or are. Boceprevir (BOC) is a hepatitis C virus (HCV) NS3/4A protease inhibitor used in combination with pegylated interferon + ribavirin for the treatment of HCV.

In that study, concurrent administration of pravastatin (40 mg, single. Recommendations for coadministration of pravastatin with darunavir have been based on a small PK study that showed substantial intersubject variability in the impact of interactions between the two drugs. May 18, 2012.

Department of Health and Human Services (HHS) under grant number U1OHA28686 (AIDS Education and Training Centers National Coordinating Resource Center) awarded to the François-Xavier Bagnoud Center from the Rutgers University School of Nursing. No percentage of this project was financed with non-governmental sources. Government. This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S.

Boceprevir and aprevir, the hepatitis C virus (HCV) serine protease inhibitors, are likely to play important roles in the treatment of individuals with HIV/HCV coinfection, as well as in persons with HCV monoinfection. However, both boceprevir and aprevir are inhibitors and substrates of.

Few studies have examined interactions between PIs and other corticosteroids. April 17, 2012. It has been demonstrated previously that ritonavir significantly increases serum levels of inhaled and intranasal fluticasone and that coadministration with fluticasone should be avoided. At the 19th.

Coauthor: Susa Coffey, MD; Medical Editor, AETC National Resource Center.

It must administered with ritonavir, and used in combination with other antiretrovirals. August 1, 2014. For infants, it may be. An oral powder formulation of atazanavir has been approved by the FDA for use in infants and children older than 3 months and weighing 10 to <25 kg.

Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. October 1, 2015. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted.

April 28, 2015. The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and.

Drug interactions